Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy

Table 2 Clinicopathological profiles of the patients treated with NACT (stratified by TIN after NACT)

Characteristic		Low TIN after NACT	High TIN after NACT	P
Characteristic		N = 111	N = 22	P
Age		54.02 ± 10.872	54.82 ± 10.312	0.804
< 40		12	2	0.810
> 40		99	20	0.810
No menopause		42	7	0.593
Menopause		69	15	0.593
T1		17	3	0.791
T2		68	12
T3		21	5
T4		5	2
N0		33	3	0.382
N1		21	6
N2		25	7
N3		32	6
Stage I		9	0	0.214
Stage II		40	6
Stage III		62	16
HR+		77	11	0.079
HR-		34	11	0.079
Her-2 positive		11	6	0.026
Her-2 negative		100	16	0.026
TNBC vs		23	5	0.833
No TNBC		88	17	0.833
Remission vs		96	8	< 0.001
No remission		15	14	< 0.001
Recurrence vs		15	9	0.002
No recurrence		96	13	0.002
CR	TEC	60	11	0.089
	EC	20	3
	EC	9	3
	TX	22	5

Abbreviation: HR Hormone receptor, Her-2 Human epidermal growth factor receptor-2, TNBC Triple negative breast cancer, NACT Neoadjuvant chemotherapy, CR Chemical regime, TEC Docetaxel + anthracyclines + cyclophosphamide, EC Anthracyclines + cyclophosphamide, TC Docetaxel + cyclophosphamide, DP Docetaxel + platinum

ISSN: 1471-2407